# A Phase 2 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.

> **NCT04503629** · PHASE2 · COMPLETED · sponsor: **Sihuan Pharmaceutical Holdings Group Ltd.** · enrollment: 150 (actual)

## Conditions studied

- Duodenal Ulcer，DU

## Interventions

- **DRUG:** Anaprazole Sodium
- **DRUG:** Anaprazole Sodium
- **DRUG:** Rabeprazole sodium

## Key facts

- **NCT ID:** NCT04503629
- **Lead sponsor:** Sihuan Pharmaceutical Holdings Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-09
- **Primary completion:** 2019-05-17
- **Final completion:** 2019-05-17
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2020-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04503629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04503629, "A Phase 2 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT04503629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*